Next Article in Journal
Astaxanthin n-Octanoic Acid Diester Ameliorates Insulin Resistance and Modulates Gut Microbiota in High-Fat and High-Sucrose Diet-Fed Mice
Next Article in Special Issue
d-glutamate and Gut Microbiota in Alzheimer’s Disease
Previous Article in Journal
High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout
Open AccessReview

Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder

Department of Psychiatry, Gil Medical Center and Gachon University College of Medicine, Incheon 21565, Korea
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(6), 2148; https://doi.org/10.3390/ijms21062148
Received: 19 February 2020 / Revised: 12 March 2020 / Accepted: 19 March 2020 / Published: 20 March 2020
(This article belongs to the Special Issue Biomarkers Guided Diagnosis and Therapy: Toward Precision Psychiatry)
The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been published on biomarkers for treatment response and recurrence of MDD using various methods such as brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). The results have been inconsistent, and we hypothesize that this could be due to small sample size; different study design, including eligibility criteria; and differences in the imaging and analysis techniques. In the future, we suggest a more sophisticated research design, larger sample size, and a more comprehensive integration including genetics to establish biomarkers for the prediction of treatment response and recurrence of MDD. View Full-Text
Keywords: biomarker; major depressive disorder; genetics; neuroimaging; recurrence; treatment response biomarker; major depressive disorder; genetics; neuroimaging; recurrence; treatment response
MDPI and ACS Style

Kang, S.-G.; Cho, S.-E. Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder. Int. J. Mol. Sci. 2020, 21, 2148.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop